Latest Financial Position News

Rimfire Pacific Mining's December 2024 quarterly report reveals its highest-grade scandium intercept to date at Murga and strategic expansion with the Rabbit Trap Scandium Project acquisition, alongside promising cobalt-copper results at Broken Hill.

Mad Paws Holdings Limited has reported a strong Q2 FY25 with a 328% increase in cash EBITDA and a 16% rise in marketplace revenue, driven by a strategic above-the-line marketing campaign.

Credit Corp Group has reported a robust 32% rise in underlying NPAT for H1 FY2025, driven by strong US collections and consumer lending growth, while reaffirming its full-year guidance and announcing a healthy interim dividend.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

Credit Corp Group Limited has reported a remarkable turnaround for the half-year ended 31 December 2024, posting a 464% increase in profit after tax to $44.1 million and a 45% rise in revenue to $271.5 million. The company also declared a fully franked interim dividend of 32 cents per share, signalling confidence in ongoing growth.

Omega Oil and Gas Limited has successfully raised A$7 million in a strongly supported institutional placement, positioning the company to advance its Canyon-1H fracture stimulation and appraisal program.

Heavy Rare Earths Limited (ASX:HRE) advanced its uranium exploration footprint in South Australia with a key asset acquisition and bolstered its balance sheet through a $2.46 million capital raise during the December 2024 quarter.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Intelligent Monitoring Group Limited has reaffirmed its FY25 adjusted EBITDA guidance above $38 million, reporting a robust $7.9 million operating cash flow for the first half of 2025. The company is advancing its strategic acquisitions and launching innovative video guarding services poised to disrupt the security sector.

Change Financial Limited reported a robust Q2 FY25 with revenue surging 53% year-on-year, driven by its expanding PaaS platform, while strategically exiting its loss-making US operations to sharpen focus on Australia and New Zealand.

Doctor Care Anywhere delivered positive cash flow and revenue growth at the top of guidance in Q4 2024, while navigating a strategic shift with new leadership appointments and the closure of secondary care pathways.

Island Pharmaceuticals reports promising safety and anti-dengue activity in its Phase 2a trial of ISLA-101 and has commenced the Phase 2b therapeutic arm, backed by a fresh A$3.5 million capital raise.